Molecular Diagnostics for Melanoma

TRAMA

In Molecular Diagnostics for Melanoma: Methods and Protocols, expert researchers and clinicians in the field of melanoma provide updated information on biomarkers and assays for diagnosis, prognosis, and assays predicting response to treatment for routine testing. The focus of the volume is on biomarkers with established clinical validity rather than those on early discovery stage. With additional in-depth discussion of the molecular biology and pathology of melanoma, treatment options in adjuvant and metastatic setting, and implications of biomarker testing for clinical management of melanoma patients.Written in the highly successful Methods in Molecular Biology series format, chapters include extensive introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and key tips on troubleshooting and avoiding known pitfalls.Comprehensive and practical, Molecular Diagnostics for Melanoma: Methods and Protocols seeks to provide both clinicians and scientists with technical information and extensive background information on the wide ranging approaches available in the field of diagnostics of melanoma.

SOMMARIO

Part I. Clinical Challenges and Current Status of Treatment of Melanoma 1. Novel Insights/translational Implication from the Emerging Biology of Melanoma                      Antoni Ribas 2. Emerging Clinical Issues in Melanoma in the Molecularly Targeted Era            Ryan J. Sullivan and Michael B. Atkins 3. Integrating Molecular Biomarkers Into Current Clinical Management In Melanoma            Ragini Kudchadkar, Geoffrey Gibney, and Vernon K. Sondak Part II. Biomarkers for Prediction of Response and Resistance to Treatment 4. Advances in Adjuvant Therapy: Potential for Prognostic and Predictive Biomarkers            Diwakar Davar, Ahmad A. Tarhini, Helen Gogas, and John M. Kirkwood 5. Immunologic Monitoring of Cancer Vaccine Trials Using the ELISPOT Assay               Lisa H. Butterfield and Mary Jo Buffo 6. Markers for Anti-Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) Therapy in Melanoma            Michael A. Postow, Jianda Yuan, Shigehisa Kitano, Alexander M. Lesokhin, and Jedd D. Wolchok 7. Marker Utility for Combination Therapy            Ester Simeone, Antonio M. Grimaldi, and Paolo A. Ascierto8. Assaying for BRAF V600E in Tissue and Blood in Melanoma            David J. Panka, James W. Mier, and Ryan J. Sullivan 9. Selecting Patients for KIT Inhibition in Melanoma            Richard D. Carvajal, Omid Hamid, and Cristina R. Antonescu 10. Detecting Mechanisms of Acquired BRAF inhibitor Resistance in Melanoma            Roger Lo and Hubing Shi 11. Current Status of Diagnostic and Prognostic Markers in Melanoma                   Danielle Levine and David E. Fisher 12. Chromosomal Copy Number Analysis in Melanoma Diagnostics             Jeffrey P. North, Swapna Vemula, and Boris C. Bastian 13. Construction and Analysis of Multi-Parameter Prognostic Models for Melanoma Outcome            Bonnie E. Gould Rothberg and David L. Rimm 14. Immunohistochemical Diagnostic and Prognostic Markers for Melanoma            Mehdi Nosrati and Mohammed Kashani-Sabet 15. Lymphatic Invasion as a Prognostic Biomarker in Primary Cutaneous Melanoma            Xiaowei Xu, Phyllis A. Gimotty, DuPont Guerry, Giorgos Karakousis, and David E. Elder 16. Tumor Infiltrating Lymphocytes and Their Significance in Melanoma Prognosis            Tobias Schatton, Richard A. Scolyer, John F. Thompson, and Martin C. Mihm, Jr.  17. Pathological Staging of Melanoma            David E. Elder 18. Genotyping of Human Leukocyte Antigen (HLA) Ancestral Haplotypes as Prognostic Marker in Cancer Using PCR Analysis            Lisa Villabona, Emilia Andersson, Maddalena Marchesi, and Giuseppe V. Masucci 19. B7-H Abnormalities in Melanoma and Clinical Relevance            Barbara Seliger 20. Melanoma Susceptibility Genes and Risk Assessment            Alexander Marxuka-Alcalá, Michele Jacobs Gabree, and Hensin Tsao Part IV. Uveal Melanoma 21. Clinical, Pathologic, and Imaging Features, and Biological Markers of Uveal Melanoma            Hans E. Grossniklaus and Alia B. Rashid 22. A Prognostic Test to Predict Risk of Metastasis in Uveal Melanoma Based on a 15-Gene Expression Profile            J. William Harbour 23. Molecular Karyotyping for Detection of Prognostic Markers in Fine Needle Aspirate Biopsy Samples of Uveal Melanoma            Arupa Ganguly, Jennifer Richards-Yutz, and Kathryn G. Ewens Part V. Emerging Markers/Targets in Melanoma24. ERBB4 Mutation Analysis: Emerging Molecular Target for Melanoma Treatment            Christopher Lau, Keith J. Killian, Yardena Samuels, and Udo Rudloff 25. Epigenetic Markers of Prognosis in Melanoma            Luca Sigalotti, Elisabetta Fratta, Giulia Parisi, Sandra Coral, and Michele Maio 26. Isolation of Melanoma Cell Subpopulations Using Negative Selection            Ana Slipicevic, Rajasekharan Somasundaram, Katrin Sproesser, and Meenhard Herlyn 27. Circulating Tumor Cells as Prognostic Biomarkers in Cutaneous Melanoma Patients            Eiji Kiyohara, Keisuke Hata, Stella Lam, and Dave S. B. Hoon 28. Detection of Chondroitin Sulfate Proteoglycan 4 (CSPG4) in Melanoma            Yangyang Wang, Francesco Sabbatino, Xinhui Wang, and Soldano Ferrone 29. Targeting Damage Associated Molecular Pattern Molecules (DAMPs) and DAMP Receptors in Melanoma            Brian A. Boone and Michael T. Lotze 30. The Clinical Use of PET/CT in the Evaluation of MelanomaKhun Visith Keu and Andrei H. Iagaru Part VI. Emerging Technologies for Marker Validation 31. Immune System Functional Pathway Analysis Using Single Cell Network Profiling (SCNP): A Novel Tool in Cancer Immunotherapy            Alessandra Cesano 32. Quantitative and Spatial Image Analysis of Tumor and Draining Lymph Nodes Using Immunohistochemistry and High Resolution Multispectral Imaging to Predict Metastasis            Kim R.M. Blenman and Peter P. Lee 33. COLD-PCR Enriches Low-Level Variant DNA Sequences and Increases the Sensitivity of Genetic Testing            Elena Castellanos-Rizaldos, Coren A. Milbury, Minakshi Guha, and G. Mike Makrigiorgos 34. Isolation of Circulating MicroRNAs from Microvesicles found in Human Plasma            John F. Quackenbush, Pamela B. Cassidy, Lawrence M. Pfeffer, Kenneth M. Boucher, Jason E. Hawkes, Susan R. Pfeffer, Levy Kopelovich, and Sancy A. Leachman 35. Detection of Circulating Tumor Cells by Photoacustic Flowmetry            Ryan M. Weight and James A. Viator Part VII. Marker Validation Requirements for Clinical Applicability 36. Statistical Design and Evaluation of Biomarker Studies            Kevin K. Dobbin 37. Tissue Resources for Clinical Use and Marker Studies in Melanoma            Jonathan L. Curry, Michael A. Davies, Tiffany L. Calderone, Katherine Nathanson, Victor G. Prieto, and Jeffrey Gershenwald.

ALTRE INFORMAZIONI

• Condizione: Nuovo
• ISBN: 9781627037266
• Collana: Methods in Molecular Biology
• Dimensioni: 254 x 178 mm Ø 15073 gr
• Formato: Copertina rigida
• Illustration Notes: XXIII, 712 p. 110 illus., 94 illus. in color.
• Pagine Arabe: 712
• Pagine Romane: xxiii